Novo Nordisk CEO to face Senate questions amid pricing controversy

Novo Nordisk (NOV: N) is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee.

In June, Senator Bernie Sanders revealed that Mr Jørgensen had agreed to testify on a solo panel before the Senate Committee on Health, Education, Labor, and Pensions (HELP), prompting the cancellation of a planned vote to issue a subpoena.

Mr Sanders stated that Mr Jørgensen would be questioned about “the outrageously high prices that Novo Nordisk charges Americans for their blockbuster drugs, Ozempic (semaglutide) and Wegovy (semaglutide).”